Identifying aggressive forms of endometrioid-type endometrial cancer: New insights into molecular subtyping

Expert Review of Anticancer Therapy

Volumn 15, Issue 1, 2014, Pages 1-3

  Liu, Yuexin ^a   Broaddus, Russell R ^a   Zhang, Wei ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

cancer therapeutics; CTNNB1 mutation; endometrial carcinoma; molecular subtyping; wnt signaling pathway

Indexed keywords

BETA CATENIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; TRASTUZUMAB; TUMOR MARKER;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CPG ISLAND; CTNNB1 GENE; ENDOMETRIUM CANCER; GENE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENOTYPE; GLIOMA; HORMONAL THERAPY; HUMAN; IDH1 GENE; IDH2 GENE; MOLECULAR TYPING; REVIEW; TUMOR INVASION; DNA MUTATIONAL ANALYSIS; ENDOMETRIOID CARCINOMA; ENDOMETRIUM TUMOR; FEMALE; GENETICS; PATHOLOGY; TRENDS;

BIOMARKERS, TUMOR; CARCINOMA, ENDOMETRIOID; DNA MUTATIONAL ANALYSIS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; NEOPLASM INVASIVENESS;

EID: 84919832822     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2015.992420     Document Type: Review

References (20)

1. Zhang W, Cheng SY, Hou LF, et al. Genomics in personalized cancer medicine and its impact on early drug development in China: report from the 6th Annual Meeting of the US Chinese Anti-Cancer Association (USCACA) at the 50th ASCO Annual Meeting. Chin J Cancer 2014; 33(8):371-5
2. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumors. Nature 2012; 490(7418):61-70
3. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360(8):765-73
4. Zhang W. TCGA divides gastric cancer into four molecular subtypes: implications for individualized therapeutics. Chin J Cancer 2014;33(10):469-70
5. TCGA Research Network. The somatic genomic landscape of glioblastoma. Cell 2013;155(2):462-77
6. Yang D, Khan S, Sun Y, et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011;306(14):1557-65
7. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63(1):11-30
8. Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497(7447):67-73
9. Salvesen HB, Carter SL, Mannelqvist M, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci U S A 2009; 106(12):4834-9
10. Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 2011;11(8): 597-608
11. Liu YX, Patel L, Mills GB, et al. Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. J Natl Cancer Inst 2014;106(8; dju245
12. Myers A, Barry WT, Hirsch MS, et al. beta-Catenin mutation in recurrent FIGO IA grade 1 endometrioid endometrial cancers. Gynecol Oncol 2014;134(2):426-7
13. Matias-Guiu X, Prat J. Molecular pathology of endometrial carcinoma. Histopathology 2013;62(1):111-23
14. Mhawech-Fauceglia P, Wang D, Samrao D, et al. Trefoil factor family 3 (TFF3) expression and its interaction with estrogen receptor (ER) in endometrial adenocarcinoma. Gynecol Oncol 2013; 130(1):174-80
15. Liu C, Li Y, Semenov M, et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002;108(6): 837-47
16. NCI. Available from: www.cancer.gov/drugdictionary?cdrid=696436
17. Liu J, Pan S, Hsieh MH, et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci USA 2013;110(50):20224-9
18. Dickson MA. Molecular pathways: CDK4 inhibitors for cancer therapy. Clin Cancer Res 2014;20(13):3379-83
19. Ramirez PT, Frumovitz M, Bodurka DC, et al. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol 2004;95(1):133-8
20. Feliciano P. Inhibitors of mutant IDH1 and IDH2. Nat Genet 2013;45(5):477